Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309363079> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4309363079 abstract "Abstract Background Pediatric heart transplant recipients are at risk for complications from prolonged exposure to immunosuppressive drugs, pharmacokinetic challenges in maintaining consistent immunosuppression, and medication non‐adherence. Basiliximab (BAS), an interleukin‐2 receptor antagonist, is used for induction therapy across many pediatric heart transplant centers, but use as maintenance immunosuppression has not been well described. Methods This was a retrospective, single pediatric center cohort study of heart transplant recipients who received BAS for maintenance immunosuppression (defined as >2 monthly doses) from January 1, 2011, to December 31, 2021. Results Ten patients met study criteria with a median age of 17.5 (5–22) years and median 9.6 (1.2–18.9) years since transplant at time of BAS initiation. The primary indications for BAS use were recurrent rejection ( n = 4), fluctuating immunosuppression levels ( n = 3), and renal dysfunction ( n = 3). A median of 5.5 (3–32) monthly BAS doses were received. Three patients had a rejection event while on BAS. Calcineurin inhibitor exposure was reduced in 70% of patients. Three of the 10 patients were alive at last follow‐up. There was one documented infection during BAS use, and no hypersensitivity reactions. Conclusions Monthly BAS infusions were well tolerated and allowed for reduced calcineurin inhibitor exposure in most patients. Mortality commonly occurred despite BAS use, potentially reflecting the acuity of this patient cohort. BAS can be considered for maintenance immunosuppression in pediatric patients with fluctuating immunosuppressive levels and/or renal dysfunction. More studies are needed to determine long‐term outcomes and explore expanded use of BAS in the pediatric heart transplant population." @default.
- W4309363079 created "2022-11-26" @default.
- W4309363079 creator A5036152301 @default.
- W4309363079 creator A5041812101 @default.
- W4309363079 creator A5058530779 @default.
- W4309363079 creator A5087087082 @default.
- W4309363079 date "2022-11-17" @default.
- W4309363079 modified "2023-10-17" @default.
- W4309363079 title "Basiliximab as maintenance immunosuppression in heart transplant recipients: A single pediatric center experience" @default.
- W4309363079 cites W2010402238 @default.
- W4309363079 cites W2027880302 @default.
- W4309363079 cites W2072030208 @default.
- W4309363079 cites W2077684987 @default.
- W4309363079 cites W2089539530 @default.
- W4309363079 cites W2092180284 @default.
- W4309363079 cites W2134810421 @default.
- W4309363079 cites W2136258760 @default.
- W4309363079 cites W2155965977 @default.
- W4309363079 cites W2158883043 @default.
- W4309363079 cites W2163967332 @default.
- W4309363079 cites W2320968951 @default.
- W4309363079 cites W2406877319 @default.
- W4309363079 cites W2922465107 @default.
- W4309363079 cites W2970050916 @default.
- W4309363079 cites W4226196261 @default.
- W4309363079 cites W943967856 @default.
- W4309363079 doi "https://doi.org/10.1111/petr.14438" @default.
- W4309363079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36397270" @default.
- W4309363079 hasPublicationYear "2022" @default.
- W4309363079 type Work @default.
- W4309363079 citedByCount "2" @default.
- W4309363079 countsByYear W43093630792023 @default.
- W4309363079 crossrefType "journal-article" @default.
- W4309363079 hasAuthorship W4309363079A5036152301 @default.
- W4309363079 hasAuthorship W4309363079A5041812101 @default.
- W4309363079 hasAuthorship W4309363079A5058530779 @default.
- W4309363079 hasAuthorship W4309363079A5087087082 @default.
- W4309363079 hasConcept C126322002 @default.
- W4309363079 hasConcept C128057223 @default.
- W4309363079 hasConcept C167135981 @default.
- W4309363079 hasConcept C187212893 @default.
- W4309363079 hasConcept C2777288759 @default.
- W4309363079 hasConcept C2778849806 @default.
- W4309363079 hasConcept C2780252810 @default.
- W4309363079 hasConcept C2781307858 @default.
- W4309363079 hasConcept C2909675724 @default.
- W4309363079 hasConcept C2911091166 @default.
- W4309363079 hasConcept C71924100 @default.
- W4309363079 hasConcept C72563966 @default.
- W4309363079 hasConceptScore W4309363079C126322002 @default.
- W4309363079 hasConceptScore W4309363079C128057223 @default.
- W4309363079 hasConceptScore W4309363079C167135981 @default.
- W4309363079 hasConceptScore W4309363079C187212893 @default.
- W4309363079 hasConceptScore W4309363079C2777288759 @default.
- W4309363079 hasConceptScore W4309363079C2778849806 @default.
- W4309363079 hasConceptScore W4309363079C2780252810 @default.
- W4309363079 hasConceptScore W4309363079C2781307858 @default.
- W4309363079 hasConceptScore W4309363079C2909675724 @default.
- W4309363079 hasConceptScore W4309363079C2911091166 @default.
- W4309363079 hasConceptScore W4309363079C71924100 @default.
- W4309363079 hasConceptScore W4309363079C72563966 @default.
- W4309363079 hasIssue "2" @default.
- W4309363079 hasLocation W43093630791 @default.
- W4309363079 hasLocation W43093630792 @default.
- W4309363079 hasOpenAccess W4309363079 @default.
- W4309363079 hasPrimaryLocation W43093630791 @default.
- W4309363079 hasRelatedWork W1971121528 @default.
- W4309363079 hasRelatedWork W2005357624 @default.
- W4309363079 hasRelatedWork W2007050204 @default.
- W4309363079 hasRelatedWork W2022671737 @default.
- W4309363079 hasRelatedWork W2114862870 @default.
- W4309363079 hasRelatedWork W2317216770 @default.
- W4309363079 hasRelatedWork W2369603220 @default.
- W4309363079 hasRelatedWork W2795273224 @default.
- W4309363079 hasRelatedWork W4321004105 @default.
- W4309363079 hasRelatedWork W4387166227 @default.
- W4309363079 hasVolume "27" @default.
- W4309363079 isParatext "false" @default.
- W4309363079 isRetracted "false" @default.
- W4309363079 workType "article" @default.